Search results for "Antipsychotics"

showing 10 items of 23 documents

Role of serotonin in central dopamine dysfunction

2010

The interaction between serotonin (5-HT) and dopamine (DA)-containing neurons in the brain is a research topic that has raised the interest of many scientists working in the field of neuroscience since the first demonstration of the presence of monoamine-containing neurons in the mid 1960. The bulk of neuroanatomical data available clearly indicate that DA-containing neurons in the brain receive a prominent innervation from serotonin (5-hydroxytryptamine, 5-HT) originating in the raphe nuclei of the brainstem. Compelling electrophysiological and neurochemical data show that 5-HT can exert complex effects on the activity of midbrain DA neurons mediated by its various receptor subtypes. The m…

Mesocorticolimbic DA systemNigrostriatal DA systemReceptor Serotonin 5-HTParkinson's diseaseBrain microdialysisAntidepressantDopaminergic functionAntidepressantsSettore BIO/09 - Fisiologia5-HT receptorAntipsychoticParkinson diseaseMicrodialysinervous systemSingle cell recordingDrug addictionAntidepressants;Antipsychotics;Dopaminergic function;Drug addiction;5-HT receptors;Mesocorticolimbic DA system;Microdialysis;Nigrostriatal DA system;Parkinson disease;Single cell recordingAntipsychotic drugs
researchProduct

Treatments used for obsessive-compulsive disorder-An international perspective.

2018

Objective The objective of this study was to characterise international trends in the use of psychotropic medication, psychological therapies, and novel therapies used to treat obsessive–compulsive disorder (OCD). Methods Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their samples. Consistency of summary statistics across countries was evaluated. Results The study surveyed 19 expert centres from 15 countries (Argentina, Australia, Brazil, China, Germany, Greece, India, Italy, Japan, Mexico, Portugal, South Africa, Spain, the United Kingdom, and the United States) providing a total sample of 7,340 participants. Fluoxetine (n = 972; 13…

MaleObsessive-Compulsive DisorderInternationalitymedicine.medical_treatmentDeep Brain StimulationSocial SciencesFluvoxamineBENZODIAZEPINASpharmacotherapyBenzodiazepines0302 clinical medicinePharmacology (medical)TERAPIA PSICOANALITICAPSICOFARMACOLOGIAantipsychotics; benzodiazepines; cross-cultural study; obsessive-compulsive disorder; pharmacotherapy; selective serotonin reuptake inhibitorsMiddle Aged3. Good healthExposure and response preventionantipsychotics; benzodiazepines; cross-cultural study; obsessive–compulsive disorder; pharmacotherapy; selective serotonin reuptake inhibitorsNeurologyPsychiatry and Mental HealthSerotonin Uptake Inhibitorscross-cultural studyAripiprazoleFemalebenzodiazepineSelective Serotonin Reuptake Inhibitorsmedicine.drugPsychosurgeryAntipsychotic AgentsAdultmedicine.medical_specialty:Ciências da Saúde [Ciências Médicas]Ciências Médicas::Ciências da SaúdeSerotonin reuptake inhibitor03 medical and health sciencesANTIPSICOTICOSobsessive–compulsive disorderselective serotonin reuptake inhibitorsmedicinePSICOTROPICOSHumansAntipsychoticPsychiatryFARMACOTERAPIAFluoxetineRisperidoneantipsychotics; benzodiazepines; cross-cultural study; obsessive–compulsive disorder; pharmacotherapy; selective serotonin reuptake inhibitors; Neurology; Neurology (clinical); Psychiatry and Mental Health; Pharmacology (medical)Science & Technologyselective serotonin reuptake inhibitorbusiness.industryTRASTORNO OBSESIVO COMPULSIVO030227 psychiatryantipsychoticPsychosurgeryantipsychoticsNeurology (clinical)business030217 neurology & neurosurgerySEROTONINAHuman psychopharmacology
researchProduct

Use of Antipsychotics in Patients with Behavioral and Psychological Symptoms of Dementia: Results of a Spanish Delphi Consensus.

2020

<b><i>Background:</i></b> Behavioral and psychological symptoms of dementia (BPSD) are difficult to manage and associated with poor outcome. <b><i>Objectives:</i></b> The aim of this study was to reach consensus on the use of antipsychotics in patients with BPSD in Spain. <b><i>Methods:</i></b> A qualitative, multicenter, two-round Delphi study was carried out, with the participation of specialists involved in the care of dementia patients throughout Spain. They completed a 76-item questionnaire related to the identification of BPSD, treatment with antipsychotics, follow-up of patients, barriers for the use of atypical …

Malemedicine.medical_specialtyNeurologyConsensusDelphi Techniquemedicine.drug_classCognitive NeuroscienceDelphi methodAtypical antipsychoticBehavioral SymptomsPsychiatric historyQuality of lifemedicineDementiaAntipsychoticsHumansMedical prescriptionPsychiatryAgedGeriatricsbusiness.industryBehavioral and psychological symptomsMiddle Agedmedicine.diseaseNeuropsychiatric symptomsPsychiatry and Mental healthSpainQuality of LifeDementiaFemaleGeriatrics and GerontologybusinessAlzheimer’s diseaseAntipsychotic AgentsResearch ArticleDementia and geriatric cognitive disorders
researchProduct

Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disor…

2022

In this prospective study, we assessed the effectiveness and acceptability of paliperidone palmitate 1-month (PP1M) and aripiprazole monohydrate (AM) over 1-year follow-up. We included 195 subjects (117 treated with PP1M and 78 with AM) with schizophrenia spectrum disorders from real-world settings. We estimated no differences in hospitalization (Odds Ratio=1.59; p = 0.12), symptoms improvement (p = 0.90 adjusted for baseline severity), and discontinuation (Hazard Ratio=0.72; p = 0.20) at study endpoint. Although current evidence suggests the possible superiority of AM over PP1M, our findings showed comparable effectiveness between these drugs. Additional studies in real-world settings with…

Long-acting injectable antipsychoticPaliperidone palmitate 1-monthAripiprazoleAripiprazole monohydrateLong-acting injectable antipsychoticsPsychiatry and Mental healthPaliperidone PalmitateSchizophreniaHumansProspective StudiesSettore MED/25 - PsichiatriaBiological PsychiatryAripiprazole monohydrate; Long-acting injectable antipsychotics; Paliperidone palmitate 1-monthAntipsychotic Agents
researchProduct

The Role of Attitudes Toward Medication and Treatment Adherence in the Clinical Response to LAIs: Findings From the STAR Network Depot Study

2021

Background: Long-acting injectable (LAI) antipsychotics are efficacious in managing psychotic symptoms in people affected by severe mental disorders, such as schizophrenia and bipolar disorder. The present study aimed to investigate whether attitude toward treatment and treatment adherence represent predictors of symptoms changes over time.Methods: The STAR Network “Depot Study” was a naturalistic, multicenter, observational, prospective study that enrolled people initiating a LAI without restrictions on diagnosis, clinical severity or setting. Participants from 32 Italian centers were assessed at three time points: baseline, 6-month, and 12-month follow-up. Psychopathological symptoms, att…

Psychiatrypsychotic symptomtherapeutic allianceRC435-571drugantipsychoticPsychiatry and Mental healthantipsychoticsadherence; antipsychotics; attitude; drug; long-acting injectable; psychotic symptoms; therapeutic alliancepsychotic symptomsattitudeadherencelong-acting injectableOriginal ResearchFrontiers in Psychiatry
researchProduct

Off-label long acting injectable antipsychotics in real-world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR Ne…

2022

Introduction: Information on the off–label use of Long–Acting Injectable (LAI) antipsychotics in the real world is lacking. In this study, we aimed to identify the sociodemographic and clinical features of patients treated with on– vs off–label LAIs and predictors of off–label First– or Second–Generation Antipsychotic (FGA vs. SGA) LAI choice in everyday clinical practice. Method: In a naturalistic national cohort of 449 patients who initiated LAI treatment in the STAR Network Depot Study, two groups were identified based on off– or on–label prescriptions. A multivariate logistic regression analysis was used to test several clinically relevant variables and identify those associated with th…

Long-acting injectable antipsychoticCross-Sectional StudiesOff-labelPersonality disorderBipolar disorderDelayed-Action PreparationsSchizophreniaHumansBipolar disorder; Long-acting injectable antipsychotics; Off-label; Personality disorder; Schizophrenia; Cross-Sectional Studies; Delayed-Action Preparations; Humans; Off-Label Use; Antipsychotic Agents; SchizophreniaOff-Label UseSettore MED/25 - PsichiatriaLong-acting injectable antipsychoticsAntipsychotic Agents
researchProduct

The family-oriented Open Dialogue approach in the treatment of first-episode psychosis : nineteen–year outcomes

2018

Open Dialogue (OD) is a family-oriented early intervention approach which has demonstrated good outcomes in the treatment of first-episode psychosis (FEP). Nevertheless, more evidence is needed. In this register-based cohort study the long-term outcomes of OD were evaluated through a comparison with a control group over a period of approximately 19 years. We examined the mortality, the need for psychiatric treatment, and the granting of disability allowances. Data were obtained from Finnish national registers regarding all OD patients whose treatment for FEP commenced within the time of the original interventions (total N = 108). The control group consisted of all Finnish FEP patients who h…

MaleFamily therapyPsychological interventionlong-term follow-upwork capabilitylaw.inventionCohort Studies0302 clinical medicineRandomized controlled triallawOutcome Assessment Health CareMedicinetyökykyRegistriesFinlanddisability pensionperheterapiaMiddle AgedPsychiatry and Mental healthSchizophreniaFemalefamily therapyseurantatutkimusCohort studyAdultkuolleisuusmedicine.medical_specialtyAdolescentYoung Adult03 medical and health sciencesEarly Medical InterventionFirst episode psychosisHumansPsychiatryBiological PsychiatryAgedskitsofreniabusiness.industryDisability pensionmedicine.diseasemortalityta3124030227 psychiatryschizophreniaantipsychoticshospital admissionPsychotic DisorderstyökyvyttömyyseläkkeetObservational studybusiness030217 neurology & neurosurgeryPsychiatry Research
researchProduct

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders.

2021

Introduction The aim of this study was to describe the number and type of drugs used to treat depressive disorders in inpatient psychiatry and to analyse the determinants of potential drug-drug interactions (pDDI) and potentially inappropriate medication (PIM). Methods Our study was part of a larger pharmacovigilance project funded by the German Innovation Funds. It included all inpatients with a main diagnosis in the group of depressive episodes (F32, ICD-10) or recurrent depressive disorders (F33) discharged from eight psychiatric hospitals in Germany between 1 October 2017 and 30 September 2018 or between 1 January and 31 December 2019. Results The study included 14,418 inpatient cases.…

Epidemiologymedicine.medical_treatment0302 clinical medicineRisk FactorsMedicine and Health SciencesAntipsychoticsDrug Interactions030212 general & internal medicineDepression (differential diagnoses)Potentially Inappropriate Medication Listmedia_commonMultidisciplinaryDepressionPharmaceuticsQRDrugsAntidepressantsMiddle AgedAntidepressive AgentsAntidepressant Drug TherapyMedicineAntidepressantDrug Therapy CombinationAntipsychotic AgentsResearch ArticleDrugNeurological Drug Therapymedicine.medical_specialtyPatientsSciencemedia_common.quotation_subject03 medical and health sciencesPharmacotherapyDrug TherapyInternal medicinePharmacovigilanceMental Health and PsychiatrymedicineHumansAntipsychoticProbabilityPolypharmacyPharmacologyInpatientsbusiness.industryMood DisordersOdds ratioHealth CareLogistic ModelsMedical Risk Factorsbusiness030217 neurology & neurosurgeryReceptor Antagonist TherapyPloS one
researchProduct

Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy

2018

Background For many years, long-acting intramuscular (LAI) antipsychotics have been prescribed predominantly to chronic and severe patients, as a last resort when other treatments failed. Recently, a broader and earlier use of LAIs, particularly second-generation LAIs, has been emphasized. To date, few studies attempted to frame how this change in prescribing took place in real-world practice. Therefore, this study aimed to describe the clinical features of patients prescribed with LAIs, and to explore possible prescribing differences between first- and second-generations LAIs under ordinary clinical practice in Italy. Methods The STAR Network "Depot" Study is an observational, longitudinal…

Genetics and Molecular Biology (all)MalePediatricsEuropean PeopleBipolar DisorderCross-sectional studyEconomicsEpidemiologymedicine.medical_treatmentassessmentviruseslcsh:MedicineSocial SciencesLongitudinal StudieBiochemistryPrescriptionGeographical locations0302 clinical medicineMathematical and Statistical TechniquesBiochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)immune system diseasesEpidemiologyMedicine and Health Scienceslong-acting intramuscular (LAI) antipsychotics; clinical practice; assessment; second-generation antipsychotic (SGA) LAIsAntipsychoticsEthnicitiesLongitudinal Studieslcsh:ScienceMultidisciplinaryvirus diseasesDrugsMiddle Agedclinical practiceItalian PeopleEuropePrescriptionsItalyPhysical SciencesAripiprazoleFemaleBivariate AnalysisStatistics (Mathematics)medicine.drugHumanResearch ArticleAntipsychotic AgentsEmploymentAdultmedicine.medical_specialtyAdolescentResearch and Analysis Methods03 medical and health sciencesMental Health and PsychiatrymedicineHumansPaliperidoneBipolar disorderEuropean UnionStatistical MethodsAntipsychoticCross-Sectional StudiePharmacologyRisperidoneBiochemistry Genetics and Molecular Biology (all)business.industryMood Disorderslcsh:Rmedicine.disease030227 psychiatryAntipsychotic AgentCross-Sectional StudiesAgricultural and Biological Sciences (all)Labor EconomicsMultivariate AnalysisSchizophreniaObservational studylcsh:QPopulation Groupingslong-acting intramuscular (LAI) antipsychoticsPeople and placesbusiness030217 neurology & neurosurgerysecond-generation antipsychotic (SGA) LAIsMathematicsPLoS ONE
researchProduct

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

2017

Marco Solmi,1,2 Andrea Murru,3 Isabella Pacchiarotti,3 Juan Undurraga,4,5 Nicola Veronese,2,6 Michele Fornaro,7,8 Brendon Stubbs,2,9–11 Francesco Monaco,2 Eduard Vieta,3 Mary V Seeman,12 Christoph U Correll,13,14 André F Carvalho2,15 1Neuroscience Department, University of Padua, 2Institute for Clinical Research and Education in Medicine, Padua, Italy; 3Bipolar Disorders Unit, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain; 4Department of Psychiatry, Faculty of Medicine, Clínica Alemana Universidad del Desarrollo, 5Early Intervention Program, J. Horwitz Psychiatric Institute, Santiago, Chile; 6Na…

Olanzapinesafetymedicine.medical_specialtyside effectToxicology and Pharmaceutics (all)ReviewRM1-950psychosi03 medical and health sciencesIloperidonechemistry.chemical_compound0302 clinical medicineSertindoleJournal ArticlemedicineAsenapinePharmacology (medical)psychosisGeneral Pharmacology Toxicology and PharmaceuticstolerabilityPsychiatryLurasidoneBrexpiprazolePharmacologyChemical Health and Safetybusiness.industryMedicine (all)Transtornos PsicóticosGeneral Medicinepsychiatry3. Good health030227 psychiatryantipsychotics side effects tolerability safety psychosis psychiatryantipsychoticantipsychoticsside effectsPsychotic DisordersTolerabilitychemistryQuetiapineAntipsychotics; Psychiatry; Psychosis; Safety; Side effects; Tolerability; Medicine (all); Safety Research; Pharmacology Toxicology and Pharmaceutics (all); Chemical Health and Safety; Pharmacology (medical)Therapeutics. PharmacologyAntipsicóticosbusinessSafety Research030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugTherapeutics and Clinical Risk Management
researchProduct